Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inhalation Sciences Sweden AB's enterprise value is kr5.80 Mil.
Inhalation Sciences Sweden AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr-8.18 Mil. Therefore, Inhalation Sciences Sweden AB's EV-to-EBITDA for today is -0.71.
The historical rank and industry rank for Inhalation Sciences Sweden AB's EV-to-EBITDA or its related term are showing as below:
XSAT:ISAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.03 Med: -5.28 Max: 111.93
Current: -0.66
During the past 11 years, the highest EV-to-EBITDA of Inhalation Sciences Sweden AB was 111.93. The lowest was -45.03. And the median was -5.28.
XSAT:ISAB's EV-to-EBITDA is ranked worse than 100% of 519
companies
in the Medical Devices & Instruments industry
Industry Median: 14.48
vs XSAT:ISAB: -0.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Inhalation Sciences Sweden AB (XSAT:ISAB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inhalation Sciences Sweden AB's PE Ratio (TTM) for today is calculated as:
Inhalation Sciences Sweden AB's share price for today is kr0.1465.
Inhalation Sciences Sweden AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ISAB vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Inhalation Sciences Sweden AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhalation Sciences Sweden AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inhalation Sciences Sweden AB's EV-to-EBITDA falls into.
Inhalation Sciences Sweden AB's current Enterprise Value is kr5.80 Mil.
Inhalation Sciences Sweden AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB (XSAT:ISAB) has a EV-to-EBITDA of -0.71 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inhalation Sciences Sweden AB. According to the industry distribution chart, Inhalation Sciences Sweden AB ranks #999999 out of 519 companies in the Medical Devices & Instruments industry.
Is Inhalation Sciences Sweden AB's EV-to-EBITDA too high?
Inhalation Sciences Sweden AB's current EV-to-EBITDA is -0.71. Based on the distribution chart, Inhalation Sciences Sweden AB ranks #999999 out of 519 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inhalation Sciences Sweden AB ranks #999999 out of 519 companies for EV-to-EBITDA. This places Inhalation Sciences Sweden AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.48, based on 519 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inhalation Sciences Sweden AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhalation Sciences Sweden AB's current EV-to-EBITDA is -0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.38, compared to a current price of kr0.15 — trading 61.4% below its estimated fair value. The current EV-to-EBITDA is -0.71. Inhalation Sciences Sweden AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current EV-to-EBITDA is -0.71 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued.
The current stock price of kr0.15 is trading 61.4% below its estimated GF Value™ of kr0.38.
GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.
Key valuation signals for XSAT:ISAB:
EV-to-EBITDA: -0.71
GF Value™: kr0.38 vs. price of kr0.15 (61.4% below fair value)
No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
29GF Score
Get the complete analysis for XSAT:ISAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ISAB has been successfully added to your 
